NRx Pharma says FDA completes first-cycle review of preservative-free ketamine ANDA
Reuters2026/08/07 20:01- NRx Pharmaceuticals set an Aug. 10 investor call to discuss the FDA’s completed first-cycle review of its ANDA for preservative-free ketamine.
- The update follows the company’s earlier disclosure on the review outcome, with focus on the remaining regulatory path and commercialization plans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ant International partners with Visa (V.US) and Mastercard (MA.US) to jointly launch AI agent payment trust system
Fintech company Ant International announced on Thursday that it has reached a partnership with Visa and Mastercard to jointly establish new standards for AI agent payments, betting that consumers and businesses will increasingly use AI agents to complete transactions.
Hagerty prices upsized secondary offering of 9,250,000 Class A shares at $11.95 each
BKV prices upsized USD 500 million convertible senior notes offering
Crypto prices
More
